Form 4: Krystal Biotech Director Christopher Mason Awarded 5,000 Stock Options

Krystal Biotech, Inc. Director Christopher Mason was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year.

Summary

• Christopher Mason, a Director of Krystal Biotech, Inc. (KRYS), was awarded 5,000 stock options.
• The options have an exercise price of $137.46 per share.
• The award date for these options was June 30, 2025.
• The options will vest in equal monthly tranches over a one-year period.
• The expiration date for these options is June 30, 2035.
• Following this transaction, Christopher Mason beneficially owns 5,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director aligns their interests with shareholders and is a standard compensation practice, indicating continued commitment from the board.

Positives

• The award of stock options to Director Christopher Mason aligns his interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration date, providing a long-term incentive for the director.

Future Outlook

The stock options granted to Director Christopher Mason are designed to vest over a one-year period, indicating a future incentive structure tied to the company's performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries to attract and retain talent, and to align management incentives with long-term shareholder value creation. This practice is consistent with typical compensation structures for board members in growth-oriented companies.

Comparison to Industry Standards

• The grant of 5,000 stock options to a director is a standard form of equity compensation, comparable to practices at similar-sized biotech companies like BioNTech (BNTX) or Moderna (MRNA) which frequently use stock-based awards to incentivize their leadership.
• The exercise price of $137.46, likely the closing price on the grant date, is standard for at-the-money options grants.
• A one-year monthly vesting schedule is a common short-to-medium term incentive structure, though some companies may opt for longer vesting periods or performance-based vesting.

Stakeholder Impact

• Shareholders: Positive, as it aligns the director's financial interests with the company's long-term stock performance.
• Employees: Indirectly positive, as strong leadership incentives can benefit overall company stability and growth.

Next Steps

• The awarded stock options will vest in equal monthly tranches over the next one-year period.

Key Dates

Keywords

Krystal Biotech, KRYS, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Award, Christopher Mason